摘要
新型冠状病毒自爆发以来,迅速肆虐全国并波及海外多个地区。由于目前没有针对该病毒的特效药物和疫苗,按照习近平主席"遵循中医发展规律,传承精华,守正创新"和"中西并重"的指示精神,各地救治医院积极建立健全中西医协作机制,出台相关诊疗方案,努力实现提高治愈率、降低感染率和病亡率的目标。通过检索新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)相关诊疗方案、院士学者等通过公开渠道发表的见解及医疗研究机构等通过官方媒体报道的临床疗法,总结西医、中医及中西医结合针对COVID-19的防治方法。中西医结合治疗COVID-19在改善患者症状、缩短病程、延缓疾病进展、降低死亡率等方面具有明显优势,可在疫情防治全程发挥积极作用。
Since the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) was discovered in Hubei, it has rapidly swept across the whole country and many overseas regions. At present, there are no specific drugs and vaccines for SARS-CoV-2 in modern medicine. Therefore, the therapy is mainly symptomatic for treatment. According to the instruction-spirit of "Following the development rules of traditional Chinese medicine(TCM), inheriting the essence and keeping the integrity and innovation" and "attaching equal importance to TCM and Western medicine" by President Xi Jin-ping, many local hospitals has established and improved the cooperation mechanism between traditional and modern medicine. And many protocols on the prevention & treatment have been published. By retrieving these protocols, opinions of academicians and scholars, and clinical therapies reported by medical research institutions, we summarized the main prevention and cure methods of COVID-19, and found that the clinical application of integrative medicine protocols have obvious advantages in improving patient symptoms, shortening the course of disease, delaying the progress of disease, and reducing mortality. The integrative medicine can play an active role in COVID-19’s prevention and treatment.
作者
韩园园
赵梦冉
石垚
宋兆辉
周水平
何毅
HAN Yuan-yuan;ZHAO Meng-ran;SHI Yao;SONG Zhao-hui;ZHOU Shui-ping;HE Yi(TCM Research Center,Tasly Holding Group Co.,Ltd.,Tianjin 300410,China;State Key Laboratory of Critical Technology in Innovative Chinese Medicine,Tasly Pharmaceutical Group Co.,Ltd.,Tianjin 300410,China;Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China)
出处
《中草药》
CAS
CSCD
北大核心
2020年第4期878-882,共5页
Chinese Traditional and Herbal Drugs
基金
国家科技重大专项:中医药优势领域的创新中药关键技术开发研究(2017ZX09301005)。